Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | ICMT | O60725 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863460 | 1.00 | C3AR1 (0.48) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL4822498 | 0.95 | C3AR1 (0.46) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL3862214 | 0.94 | TDP1 (0.46) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL4819714 | 0.94 | TDP1 (0.46) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL4819526 | 0.92 | ACE (0.46) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL4816420 | 0.92 | PPARA (0.49) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL4821397 | 0.92 | C3AR1 (0.43) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL3862983 | 0.92 | PPARA (0.49) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL3863522 | 0.92 | C3AR1 (0.43) | C3AR1ACEICMTPPARAPPARG | |
| SCHEMBL4819529 | 0.92 | ACE (0.46) | C3AR1ACEICMTPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | claimed |
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266789-A1 | Substituted amino carboxylic acids | PTPRS, PPM1B, PTPRO | C3AR1 3309/4885ACE 1006/4885ICMT 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.